Mizuho initiated coverage of Dentsply Sirona (XRAY) with a Neutral rating and $21 price target Dentsply Sirona has historically benefitted from its research and development innovation, which may continue with the recent launch of Primescan 2, the analyst tells investors in a research note. However, the firm believes Dentsply is witnessing economic-related softness in both its dental consumables and equipment franchises, and points out the company also has recently voluntarily temporarily suspended its Byte clear aligner franchise.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Patterson Companies initiated with a Neutral at Mizuho
- Dentsply Sirona Inc. Class Action: Levi & Korsinsky LLP Reminds Dentsply Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 27, 2025 – XRAY
- Dentsply Sirona Appoints Interim CFO Amid Investigation
- Dentsply Sirona appoints Cueto as interim Chief Financial Officer
- Dentsply Sirona price target lowered to $24 from $36 at Barrington
Questions or Comments about the article? Write to editor@tipranks.com